A sleep laboratory in Kolkata is campaigning to normalize insurance coverage for Obstructive Sleep Apnea (OSA), a common but ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, ...

Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

The American Academy of Sleep Medicine (AASM) said it supports the FDA's approval of Zepbound as a sleep apnea treatment but ...

Washington (AFP) – US regulators on Friday approved the first drug treatment for sleep apnea, permitting the use of a weight-loss medication for the condition that affects millions of Americans.

“This is the first pharmacologic therapy that can treat obstructive sleep apnea in this way,” says Dan Skovronsky, chief scientific officer at Eli Lilly. Read More: Is Intermittent Fasting ...

(Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly ...